3,247 reports of this reaction
3.4% of all ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, manufactured by Haleon US Holdings LLC. There are 3,247 FDA adverse event reports linking ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL to FATIGUE. This represents approximately 3.4% of all 96,153 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 3,247 FDA reports for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.4% of all adverse event reports for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, making it one of the most commonly reported side effect.
If you experience fatigue while taking ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.